Pharmas Delay Spending, but Waters Says Interest Still Strong for Flagship Tools | GenomeWeb
Despite a delay in pharmaceutical spending and other “challenging economic conditions,” Waters this week said that researchers continue to express strong interest in the company’s Acquity UPLC and Synapt High Definition mass spectrometer.
Company officials made those remarks as Waters released its first-quarter earnings, which showed that revenues rose 12 percent to $371.1 million from $330.8 million a year ago, and profits surged 22 percent to $68.5 million from $56 million last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.